Prostate Cancer

The integrated radiomic-clinicopathologic nomogram (RadClip) was a better prognosticator of biochemical recurrence-free survival and adverse pathology than other standard tools.

Health literacy was associated with a reduced likelihood that a patients' screening decision would be affected by the screening-promoting effects of shared decision making.

Among patients with 6 years’ follow-up, no differences were observed between ultra-hypofractionation and conventional fractionation in the rates of clinically relevant deterioration in overall urinary bother, overall bowel bother, overall sexual bother, or global health/QoL.

The investigators drew specific attention to the impact of their findings on prostate ablation therapy.

In the ARAMIS trial, darolutamide reduced the risk of death by 31% compared with placebo in men with nonmetastatic castration-resistant prostate cancer.

The technique fails to demonstrate benefits for prostate cancer recurrence and metastases.

The researchers also found evidence supporting the role of germline variation in healthcare disparities related to prostate cancer.

“Instead of just offering a select-few treatment options, ideally you would like to be able to offer patients a whole menu of treatments and have an educated conversation regarding the risks and benefits for each of these treatment options," says Rian Dickstein, MD.

The FDA approved relugolix in December 2020 for the treatment of patients with advanced prostate cancer.

The research involved examining circulating markers of inflammation in patients with prostate cancer receiving androgen-deprivation therapy.

Because of the limitations of the research, the findings need to be considered with caution, said Lourdes Guerrios-Rivera, MD, MSc.

Urologist Adam J. Gadzinski, MD, MS, shares his excitement about the dawn of the precision medicine era in prostate cancer.

The researchers recommend patient counseling on these side effects and routine monitoring of cognitive function in patients receiving ADT.

Declan G. Murphy, MB BCh, discusses how PSMA PET/CT imaging often leads to the upstaging of a patient’s prostate tumor, as well as how the novel technique lowers the rate of equivocal findings.

The approval of the GnRH receptor antagonist is based on data from the phase 3 HERO study.

Treatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.

Murphy shares the backstory of how PSMA PET/CT imaging has emerged as a major advancement in the prostate cancer armamentarium.

The new drug application for 18F-DCFPyL is supported by results from the OSPREY and CONDOR trials.

Olaparib has "ushered in the era of precision medicine in prostate cancer," said Maha Hussain, MD.

Experts in prostate cancer, bladder cancer, kidney stones, OAB/incontinence, BPH, and sexual dysfunction recap all the key advances from 2020.

"As we slowly move toward the promise of precision medicine, it is important to understand fully this concept and the importance of testing and how it is to be used for diagnosis, management, and risk assessment," writes Raoul S. Concepcion, MD, FACS.

“Further prospective studies are warranted to identify potential mechanisms and to develop strategies that include a fall risk assessment tool to examine the risk factors for falls or fracture,” the authors wrote.